{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":6,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00412061\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RADIANT-2","nct_id":"NCT00412061","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=radiant-2-nct00412061. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"RADIANT-2","arms":[{"description":"Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.","label":"Octreotide+ Everolimus","type":"EXPERIMENTAL"},{"description":"Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.","label":"Octreotide+ Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2013-06","type":"ACTUAL"},"conditions":["Carcinoid Tumor","Malignant Carcinoid Syndrome"],"enrollment":{"count":429,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Octreotide","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Everolimus","type":"DRUG"}],"last_update":"2014-11-21","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2010-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review","timeFrame":"Time from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 10 January 2007, until cut-off date 02 April 2010"}],"references":[{"citation":"Pavel ME, Baudin E, Oberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193.","pmid":"28444114","type":"DERIVED"},{"citation":"Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013 Apr;143(4):955-962. doi: 10.1378/chest.12-1108.","pmid":"23187897","type":"DERIVED"},{"citation":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.","pmid":"22119496","type":"DERIVED"}],"start_date":{"date":"2006-12"},"study_type":"INTERVENTIONAL","title":"Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor","url":"https://clinicaltrials.gov/study/NCT00412061"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/radiant-2-nct00412061"}